PHARMACOKINETICS OF ONCE-DAILY SOFOSBUVIR OR LEDIPASVIR/SOFOSBUVIR IN HCV-INFECTED PEDIATRICS AGED 3 TO

被引：0
|
作者：
Begley, Rebecca [1 ]
Meng, Amy [1 ]
Massetto, Benedetta [1 ]
Shao, Jiang [1 ]
Yip, Christina Sze Man [1 ]
Ling, John [1 ]
Mathias, Anita [1 ]
机构：
[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
GUT | 2019年 / 68卷
关键词：
D O I：
10.1136/gutjnl-2019-IDDFabstracts.269
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
IDDF2019-A
引用
收藏
页码：A137 / A138
页数：2
相关论文
共 50 条
  • [21] Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection
    Nelson, M.
    Bhagani, S.
    Hyland, R.
    Yun, C.
    Natha, M.
    Zheng, W.
    Brainard, D.
    McHutchinson, J.
    Jackson, A.
    Ingiliz, P.
    Lutz, T.
    Rockstroh, J.
    HIV MEDICINE, 2016, 17 : 7 - 7
  • [22] PHARMACOKINETICS OF ONCE-DAILY REGIMENS OF THE NOVEL HCV NS3/4A-PROTEASE INHIBITOR TMC435350, WITH AND WITHOUT PEGIFN AND RIBAVIRIN, IN HCV-INFECTED INDIVIDUALS
    van 't Klooster, Gerben A.
    Vanwelkenhuysen, Iris
    Verloes, Rene
    Marien, Kris
    Van Remoortere, Pieter
    Simmen, Kenneth
    HEPATOLOGY, 2008, 48 (04) : 1158A - 1158A
  • [23] Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1
    Naggie, Susanna
    Cooper, Curtis
    Saag, Michael
    Yang, Jenny C.
    Stamm, Luisa M.
    Pang, Philip S.
    McHutchison, John G.
    Dieterich, Douglas
    Sulkowski, Mark S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [24] Variability of selected extracellular matrix proteins concentrations in HCV infected patients treated with sofosbuvir and ledipasvir
    Kozlowska, Agata
    Tomasiewicz, Krzysztof
    Krzowska-Firych, Joanna
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E226 - E227
  • [25] Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1
    Bhagani, S.
    Naggie, S.
    Cooper, C.
    Saag, M.
    Yang, J.
    Stamm, L.
    Pang, P.
    McHutchison, J.
    Troke, P.
    Dieterich, D.
    Sulkowski, M.
    HIV MEDICINE, 2015, 16 : 31 - 31
  • [26] Treatment uptake and real world effectiveness of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir/dasabuvir among HCV-infected persons with chronic kidney disease
    Alkadi, M. M.
    Ren, Y.
    Puenpatom, A.
    Kumar, R.
    Arduino, J. M.
    Abou-Samra, A-B
    Butt, A. A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S724 - S725
  • [27] TREATMENT UPTAKE AND REAL WORLD EFFECTIVENESS OF SOFOSBUVIR/LEDIPASVIR AND PARITAPREVIR/RITONAVIR/OMBITASVIR/DASABUVIR AMONG HCV-INFECTED PERSONS WITH CHRONIC KIDNEY DISEASE
    Alkadi, Mohamad
    Ren, Yanjie
    Puenpatom, Amy
    Kumar, Ritesh
    Arduino, Jean Marie
    Abou-Samra, Abdul-Badi
    Butt, Adeel
    GASTROENTEROLOGY, 2017, 152 (05) : S1100 - S1101
  • [28] Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in HCV Infected Populations Including Decompensated Patients and Patients With Prior Sofosbuvir Treatment Experience
    Gane, Edward
    Hyland, Rob H.
    Pang, Phil
    Symonds, William T.
    McHutchison, John G.
    Stedman, Catherine A.
    GASTROENTEROLOGY, 2014, 146 (05) : S904 - S905
  • [29] Sofosbuvir and ribavirinin in hcv-infected patients listed for liver transplantation: a cost-effectiveness analysis
    Cortesi, Paolo A.
    Mantovani, Lorenzo G.
    Ciaccio, Antonio
    Rota, Matteo
    Cesana, Giancarlo
    Strazzabosco, Mario
    Belli, Luca S.
    HEPATOLOGY, 2014, 60 : 534A - 534A
  • [30] Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
    Lee, Soon Kyu
    Lee, Sung Won
    Lee, Hae Lim
    Kim, Hee Yeon
    Kim, Chang Wook
    Song, Do Seon
    Chang, U. Im
    Yang, Jin Mo
    Yoo, Sun Hong
    Kwon, Jung Hyun
    Nam, Soon Woo
    Kim, Seok-Hwan
    Song, Myeong Jun
    Lee, Jaejun
    Yang, Hyun
    Bae, Si Hyun
    Han, Ji Won
    Nam, Heechul
    Sung, Pil Soo
    Jang, Jeong Won
    Choi, Jong Young
    Yoon, Seung Kew
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2022, 37 (06): : 1167 - +
12345